- Home
- MQT vs FULC Comparison
MQT vs FULC Comparison
Compare MQT & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQT
- FULC
- Stock Information
- Founded
- MQT 1992
- FULC 2015
- Country
- MQT United States
- FULC United States
- Employees
- MQT N/A
- FULC N/A
- Industry
- MQT Investment Bankers/Brokers/Service
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- MQT Finance
- FULC Health Care
- Exchange
- MQT Nasdaq
- FULC Nasdaq
- Market Cap
- MQT 234.8M
- FULC 221.5M
- IPO Year
- MQT N/A
- FULC 2019
- Fundamental
- Price
- MQT $10.00
- FULC $4.35
- Analyst Decision
- MQT
- FULC Hold
- Analyst Count
- MQT 0
- FULC 10
- Target Price
- MQT N/A
- FULC $7.44
- AVG Volume (30 Days)
- MQT 52.5K
- FULC 1.0M
- Earning Date
- MQT 01-01-0001
- FULC 11-13-2024
- Dividend Yield
- MQT 4.60%
- FULC N/A
- EPS Growth
- MQT N/A
- FULC N/A
- EPS
- MQT N/A
- FULC N/A
- Revenue
- MQT N/A
- FULC $80,871,000.00
- Revenue This Year
- MQT N/A
- FULC $2,820.53
- Revenue Next Year
- MQT N/A
- FULC N/A
- P/E Ratio
- MQT N/A
- FULC N/A
- Revenue Growth
- MQT N/A
- FULC 2987.86
- 52 Week Low
- MQT $8.59
- FULC $2.86
- 52 Week High
- MQT $10.67
- FULC $13.70
- Technical
- Relative Strength Index (RSI)
- MQT 25.97
- FULC 59.28
- Support Level
- MQT $10.45
- FULC $3.94
- Resistance Level
- MQT $10.67
- FULC $4.64
- Average True Range (ATR)
- MQT 0.12
- FULC 0.38
- MACD
- MQT -0.06
- FULC 0.03
- Stochastic Oscillator
- MQT 5.33
- FULC 75.00
About MQT Blackrock MuniYield Quality Fund II Inc.
BLACKROCK MUNIYIELD QUALITY FUND II, INC. is a closed-end fund. Its objective is to provide shareholders with as high a level of current income exempt from federal income taxes as is consistent with its investment policies and prudent investment management. It invests in various sectors such as Transportation, Utilities, Health, County/City/Special District/School District, Education, Housing, Corporate, and Tobacco.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.